UNDERSTANDING AND AWARENESS OF BREAST CANCERTYPES AND ASSOCIATED CONDITIONS (REVIEW)
Main Article Content
Keywords
Tumor, Early diagnosis, Malignancy, Carcinoma of Breast.
Abstract
The most frequent cancer among women that poses a serious risk to their life right now is breast
cancer diagnosed globally. A particular type of cancer that begins as a tissue-wide cell proliferation.
Breast cancer, however, does not just affect women. Survivability as a percentage has
been rising over time. Furthermore, there is a slow decline in the incidence of casualties from
cancer of the breast. Growing public awareness and screening efforts have made early diagnosis
possible. There are numerous ways to prolong life even in cases where breast cancer cannot be
cured. The significant drop in breast cancer mortality rates can be attributed to improved
treatment options, early detection, and increasing awareness. Advances in breast cancer
research are assisting medical professionals in selecting the most efficacious treatment
regimens with the aid of new discoveries and research.
References
1. Abdul Rashid S, Rahmat K, Jayaprasagam K, Alli K, Moosa F. Medullary carcinoma of the breast. (2009). Role of contrast-enhanced MRI in the diagnosis of multiple breast lesions. Biomed Imaging Interv J. 5:e27.
2. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. (2011). Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat. Rev. Clin. Oncol. 9:16–32.
3. Atif A Hashmi, Shamail Zia, Syed Rafay Yaqeen, Omer Ahmed, Ishaq Azeem Asghar, Sabeeh Islam, Anoshia Afzal, Muhammad Irfan, Fazail Zia, and Javaria Ali. Mucinous Breast Carcinoma: Clinicopathological Comparison With Invasive Ductal Carcinoma. Cureus. 2021 Mar; 13(3): e13650.
4. Bevier M, Sundquist K, Hemminki K. Risk of breast cancer in families of multiple affected women and men. Breast Cancer Res Treat. 2012 Apr;132(2):723-8.
5. Borst MJ, Ingold JA. (1993). Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast.Surgery. 114: 637-642.
6. DeSantis CE, Ma J, Gaudet MM, et al. (2019). Breast cancer statistics, 2019. CA Cancer J Clin. 69 (6):438–451.
7. Di Saverio, S., Gutierrez, J., Avisar, E., Ahn, C., & Murphy, A. (2008). A retrospective review with long-term follow-up of mucinous carcinoma of the breast: An uncommon entity that tends to occur in older women. Breast Journal, 14(1), 47-56.
8. Foschini MP, Eusebi V. ( 2009). Rare (new) entities of the breast and medullary carcinoma. Pathology. 41:48–56.
9. Fu, J., Zong, Y., Nie, J., Zhang, B., Wei, X., Wang, L., & Xu, Y. (2013). Mucinous carcinoma of the breast: A case report and review of the literature. Oncology Letters, 6(1), 271-274..
10. Guerrero MA, Ballard BR, Grau AM. (2003). Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surg Oncol. 12:27-37.
11. Harake MD, Maxwell AJ, Sukumar SA. (2001). Primary and metastatic lobular carcinoma of the breast. Clin Radiol. 56: 621-630.
12. Hanby AM, Hughes TA. (2008). In situ and invasive lobular neoplasia of the breast. Histopathology. 52:58–66.
13. Helvie MA, Paramagul C, Oberman HA, Adler DD. (1993). Invasive lobular carcinoma. Imaging features and clinical detection. Invest Radiol. 28: 202-207.
14. Ignatiadis M, Sotiriou C. (2013). Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol. 10(9):494.
15. Jacobsen BM, Horwitz KB. (2012). Progesterone receptors, their isoforms and progesterone regulated transcription. Mol Cell Endocrinol. 357(1–2):18–29.
16. Khosravi-Shahi P. (2011). Management of non-metastatic phyllodes tumors of the breast: review of the literature. Surg Oncol. 20:e143-8.
17. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. (2001). Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1)
Breast Cancer Prevention Trial. JAMA. 286(18):2251-6.
18. Lakhani S, Ellis I, Schnitt S, et al. (2012). 4th. Lyon: IARC Press; WHO Classification of Tumours of the Breast.
19. Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. (2009).Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 88: 2561-2569.
20. Li Y, Yang D, Yin X, Zhang X, Huang J, Wu Y, Wang M, Yi Z, Li H, Li H. (2019). Clinicopathological characteristics and breast cancer–specific survival of patients with single hormone receptor–positive breast cancer. JAMA Netw Open. 3(1):e1918160.
21. Lloyd J, Flanagan AM. (2000). Mammary and extramammary Paget's disease. J Clin Pathol. 53:742-749.
22. Malyuchik SS, Kiyamova RG. (2008). Medullary breast carcinoma. Exp Oncol. 30:96–101.
23. Martinez V, Azzopardi JG. (1979). Invasive lobular carcinoma of the breast: incidence and variants. Histopathology. 3: 467-488.
24. Misung Park, Dohee Kim, Sunghyub Ko, Ayoung Kim, Kyumin Mo and Hyunho Yoon. (2022). Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. Int J Mol Sci. 23(12): 6806.
25. Niewoehner CB, Schorer AE. (2008). Gynaecomastia and breast cancer in men. BMJ. 336(7646):709-13.
26. Pedersen L, Zedeler K, Holck S, Schiødt T, Mouridsen HT. (1995). Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer. 1A(13-14):2289-95.
27. Perou CM, Sørlie T, Eisen MB, Van De Rijn M, et al. (2000). Molecular portraits of human breast tumours. Nature. 406(6797):747–752.
28. Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. (2013). Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 31(25):3091-99
29. Piekarski J, Kubiak R, Jeziorski A. (2003). Clinically silent Paget disease of male nipple. J Exp Clin Cancer Res. 22: 495-496.
30. Rakha, E. A., & Ellis, I. O. (2010). Tubular carcinoma of the breast: An update. Pathology. 42(3), 214-219.
31. Rakha, E. A., & Ellis, I. O. (2010). Medullary carcinoma of the breast: Diagnostic criteria and molecular subtypes. Breast Cancer Research. 12(Suppl 3), S2.
32. Reis-Filho, J. S., & Pusztai, L. (2011). Gene expression profiling in breast cancer: Classification, prognostication, and prediction. The Lancet, 378(9805), 1812-1823.
33. Resetkova E. (2008). Pathologic aspects of inflammatory breast carcinoma: part 1. Histomorphology and differential diagnosis. Semin Oncol. 35: 25–32.
34. Rezaianzadeh A, Sepandi M, Akrami M, Tabatabaee H, Rajaeefard A, Tahmasebi S, et al.
(2014). Pathological profile of patients with breast diseases in Shiraz. Asian Pac J Cancer Prev. 15:8191–5.
35. Rosai J. (2011). Rosai and Ackerman’s Surgical Pathology. Tenth ed. Elsevier; Lyon, France: 2011.
36. Rosen PP. (2001). Rosen's breast pathology. In: Rosen PP, ed. Inflammatory Carcinoma. Philadelphia: Lippincott Williams & Wilkins. 676–683.
37. Seetharam S, Fentiman IS: (2009). Paget's disease of the nipple. Womens Health (Lond Engl). 5:398-402.
38. Serour F, Birkenfeld S, Amsterdam E, Treshchan O, Krispin M (1998). Paget's disease of the male breast. Cancer. 62: 601-605.
39. Silverstein, M. J. (2003). Ductal Carcinoma in Situ of the Breast. Lippincott Williams and Wilkins.Soomin Ahn, Ji Won Woo, Kyoungyul Lee, and So Yeon Park. (2020). HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 54(1): 34–44.
40. Soomin A. Woo JW, Lee K, Park SY. (2020). HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 54(1):34-44.
41. Sørlie T. (2004). Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 40(18):2667–2675.
42. Timbres J, Kohut K, Caneppele M, Troy M, Schmidt MK, Roylance R, Sawyer E (2023). DCIS and LCIS: Are the Risk Factors for Developing In Situ Breast Cancer Different? Cancers (Basel).15(17):4397.
43. van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, Verschuur E, Lane J, Jonkers J, Rea DW, Wesseling J., PRECISION team. (2019). Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 121(4):285-292.
44. Vinay K, Abul KA, Jon CA, Nelson F. Robbins and Cotran. (2010). Pathologic Basis of Disease. Eight ed. Elsevier; Lyon, France.
45. Wang XX, Jiang YZ, Liu XY, Li JJ, Song CG, Shao ZM. (2016). Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database. Oncotarget.7:22665–73. (2536-2544)
2. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. (2011). Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat. Rev. Clin. Oncol. 9:16–32.
3. Atif A Hashmi, Shamail Zia, Syed Rafay Yaqeen, Omer Ahmed, Ishaq Azeem Asghar, Sabeeh Islam, Anoshia Afzal, Muhammad Irfan, Fazail Zia, and Javaria Ali. Mucinous Breast Carcinoma: Clinicopathological Comparison With Invasive Ductal Carcinoma. Cureus. 2021 Mar; 13(3): e13650.
4. Bevier M, Sundquist K, Hemminki K. Risk of breast cancer in families of multiple affected women and men. Breast Cancer Res Treat. 2012 Apr;132(2):723-8.
5. Borst MJ, Ingold JA. (1993). Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast.Surgery. 114: 637-642.
6. DeSantis CE, Ma J, Gaudet MM, et al. (2019). Breast cancer statistics, 2019. CA Cancer J Clin. 69 (6):438–451.
7. Di Saverio, S., Gutierrez, J., Avisar, E., Ahn, C., & Murphy, A. (2008). A retrospective review with long-term follow-up of mucinous carcinoma of the breast: An uncommon entity that tends to occur in older women. Breast Journal, 14(1), 47-56.
8. Foschini MP, Eusebi V. ( 2009). Rare (new) entities of the breast and medullary carcinoma. Pathology. 41:48–56.
9. Fu, J., Zong, Y., Nie, J., Zhang, B., Wei, X., Wang, L., & Xu, Y. (2013). Mucinous carcinoma of the breast: A case report and review of the literature. Oncology Letters, 6(1), 271-274..
10. Guerrero MA, Ballard BR, Grau AM. (2003). Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surg Oncol. 12:27-37.
11. Harake MD, Maxwell AJ, Sukumar SA. (2001). Primary and metastatic lobular carcinoma of the breast. Clin Radiol. 56: 621-630.
12. Hanby AM, Hughes TA. (2008). In situ and invasive lobular neoplasia of the breast. Histopathology. 52:58–66.
13. Helvie MA, Paramagul C, Oberman HA, Adler DD. (1993). Invasive lobular carcinoma. Imaging features and clinical detection. Invest Radiol. 28: 202-207.
14. Ignatiadis M, Sotiriou C. (2013). Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol. 10(9):494.
15. Jacobsen BM, Horwitz KB. (2012). Progesterone receptors, their isoforms and progesterone regulated transcription. Mol Cell Endocrinol. 357(1–2):18–29.
16. Khosravi-Shahi P. (2011). Management of non-metastatic phyllodes tumors of the breast: review of the literature. Surg Oncol. 20:e143-8.
17. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. (2001). Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1)
Breast Cancer Prevention Trial. JAMA. 286(18):2251-6.
18. Lakhani S, Ellis I, Schnitt S, et al. (2012). 4th. Lyon: IARC Press; WHO Classification of Tumours of the Breast.
19. Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. (2009).Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 88: 2561-2569.
20. Li Y, Yang D, Yin X, Zhang X, Huang J, Wu Y, Wang M, Yi Z, Li H, Li H. (2019). Clinicopathological characteristics and breast cancer–specific survival of patients with single hormone receptor–positive breast cancer. JAMA Netw Open. 3(1):e1918160.
21. Lloyd J, Flanagan AM. (2000). Mammary and extramammary Paget's disease. J Clin Pathol. 53:742-749.
22. Malyuchik SS, Kiyamova RG. (2008). Medullary breast carcinoma. Exp Oncol. 30:96–101.
23. Martinez V, Azzopardi JG. (1979). Invasive lobular carcinoma of the breast: incidence and variants. Histopathology. 3: 467-488.
24. Misung Park, Dohee Kim, Sunghyub Ko, Ayoung Kim, Kyumin Mo and Hyunho Yoon. (2022). Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. Int J Mol Sci. 23(12): 6806.
25. Niewoehner CB, Schorer AE. (2008). Gynaecomastia and breast cancer in men. BMJ. 336(7646):709-13.
26. Pedersen L, Zedeler K, Holck S, Schiødt T, Mouridsen HT. (1995). Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer. 1A(13-14):2289-95.
27. Perou CM, Sørlie T, Eisen MB, Van De Rijn M, et al. (2000). Molecular portraits of human breast tumours. Nature. 406(6797):747–752.
28. Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. (2013). Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 31(25):3091-99
29. Piekarski J, Kubiak R, Jeziorski A. (2003). Clinically silent Paget disease of male nipple. J Exp Clin Cancer Res. 22: 495-496.
30. Rakha, E. A., & Ellis, I. O. (2010). Tubular carcinoma of the breast: An update. Pathology. 42(3), 214-219.
31. Rakha, E. A., & Ellis, I. O. (2010). Medullary carcinoma of the breast: Diagnostic criteria and molecular subtypes. Breast Cancer Research. 12(Suppl 3), S2.
32. Reis-Filho, J. S., & Pusztai, L. (2011). Gene expression profiling in breast cancer: Classification, prognostication, and prediction. The Lancet, 378(9805), 1812-1823.
33. Resetkova E. (2008). Pathologic aspects of inflammatory breast carcinoma: part 1. Histomorphology and differential diagnosis. Semin Oncol. 35: 25–32.
34. Rezaianzadeh A, Sepandi M, Akrami M, Tabatabaee H, Rajaeefard A, Tahmasebi S, et al.
(2014). Pathological profile of patients with breast diseases in Shiraz. Asian Pac J Cancer Prev. 15:8191–5.
35. Rosai J. (2011). Rosai and Ackerman’s Surgical Pathology. Tenth ed. Elsevier; Lyon, France: 2011.
36. Rosen PP. (2001). Rosen's breast pathology. In: Rosen PP, ed. Inflammatory Carcinoma. Philadelphia: Lippincott Williams & Wilkins. 676–683.
37. Seetharam S, Fentiman IS: (2009). Paget's disease of the nipple. Womens Health (Lond Engl). 5:398-402.
38. Serour F, Birkenfeld S, Amsterdam E, Treshchan O, Krispin M (1998). Paget's disease of the male breast. Cancer. 62: 601-605.
39. Silverstein, M. J. (2003). Ductal Carcinoma in Situ of the Breast. Lippincott Williams and Wilkins.Soomin Ahn, Ji Won Woo, Kyoungyul Lee, and So Yeon Park. (2020). HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 54(1): 34–44.
40. Soomin A. Woo JW, Lee K, Park SY. (2020). HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 54(1):34-44.
41. Sørlie T. (2004). Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 40(18):2667–2675.
42. Timbres J, Kohut K, Caneppele M, Troy M, Schmidt MK, Roylance R, Sawyer E (2023). DCIS and LCIS: Are the Risk Factors for Developing In Situ Breast Cancer Different? Cancers (Basel).15(17):4397.
43. van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, Verschuur E, Lane J, Jonkers J, Rea DW, Wesseling J., PRECISION team. (2019). Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 121(4):285-292.
44. Vinay K, Abul KA, Jon CA, Nelson F. Robbins and Cotran. (2010). Pathologic Basis of Disease. Eight ed. Elsevier; Lyon, France.
45. Wang XX, Jiang YZ, Liu XY, Li JJ, Song CG, Shao ZM. (2016). Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database. Oncotarget.7:22665–73. (2536-2544)
Article Sidebar
Published
Feb 27, 2024
Article Details
How to Cite
Dr Sadaf Ajmal, Pari Gul, Shaista Anjum, Kiran Raees, & Kulsoom Baloch. (2024). UNDERSTANDING AND AWARENESS OF BREAST CANCERTYPES AND ASSOCIATED CONDITIONS (REVIEW). Journal of Population Therapeutics and Clinical Pharmacology, 31(2), 2536-2544. https://doi.org/10.53555/jptcp.v31i2.4656
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Dr Sadaf Ajmal
University of Karachi, Pakistan
Pari Gul
Institute of Biochemistry, University of Baluchistan, Pakistan
Shaista Anjum
Department of Botany University of Balochistan, Pakistan
Kiran Raees
Dow University of Health Sciences, Karachi, Pakistan
Kulsoom Baloch
Institute of Biochemistry, University Of Baluchistan, Pakistan
How to Cite
Dr Sadaf Ajmal, Pari Gul, Shaista Anjum, Kiran Raees, & Kulsoom Baloch. (2024). UNDERSTANDING AND AWARENESS OF BREAST CANCERTYPES AND ASSOCIATED CONDITIONS (REVIEW). Journal of Population Therapeutics and Clinical Pharmacology, 31(2), 2536-2544. https://doi.org/10.53555/jptcp.v31i2.4656